TRIGLYCERIDE-LOWERING AGENTS - FIBRATES AND NICOTINIC-ACID

被引：22

作者：

LARSEN, ML ^{[1
]}

ILLINGWORTH, DR ^{[1
]}

机构：

[1] OREGON HLTH SCI UNIV,DEPT MED,DIV ENDOCRINOL DIABET & CLIN NUTR,PORTLAND,OR 97201

来源：

CURRENT OPINION IN LIPIDOLOGY | 1993年 / 4卷 / 01期

关键词：

D O I：

10.1097/00041433-199302000-00007

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The evidence that hypertriglyceridemia is a risk factor for the premature development of coronary artery disease in certain populations remains strong. The two most effective classes of triglyceride-lowering drugs are nicotinic acid and its derivatives and the fibrates. The present review discusses recent work in which the effect of these drugs on the concentrations and metabolism of lipoproteins in human patients has been evaluated.

引用

页码：34 / 40

页数：7

共 31 条

[1] INFLUENCE OF NICOTINIC ACID ON SERUM CHOLESTEROL IN MAN [J].

ALTSCHUL, R ;

HOFFER, A ;

STEPHEN, JD .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1955, 54 (02) :558-559

[2]

AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917

[3] LOVASTATIN VERSUS BEZAFIBRATE - EFFICACY, TOLERABILITY, AND EFFECT ON URINARY MEVALONATE [J].

BEIL, FU ;

SCHRAMEYERWERNECKE, A ;

BEISIEGEL, U ;

GRETEN, H ;

KARKAS, JD ;

LIOU, R ;

ALBERTS, AW ;

ECKARDT, HG ;

TILL, AE .

CARDIOLOGY, 1990, 77 :22-32

[4] LIPIDS, DIABETES, AND VASCULAR-DISEASE - THE TIME TO ACT [J].

BETTERIDGE, DJ .

DIABETIC MEDICINE, 1989, 6 (03) :195-218

[5]

BIMMERMANN A, 1991, CURR THER RES CLIN E, V49, P635

[6] DOUBLE-BLIND COMPARISON OF BEZAFIBRATE VERSUS PLACEBO IN MALE-VOLUNTEERS WITH HYPERLIPOPROTEINEMIA [J].

BRADFORD, RH ;

GOLDBERG, AC ;

SCHONFELD, G ;

KNOPP, RH .

ATHEROSCLEROSIS, 1992, 92 (01) :31-40

[7]

DIPALMA JR, 1991, ANNU REV NUTR, V11, P169, DOI 10.1146/annurev.nu.11.070191.001125

[8] NICOTINIC-ACID FOR THE TREATMENT OF HYPERLIPOPROTEINEMIA [J].

DROOD, JM ;

ZIMETBAUM, PJ ;

FRISHMAN, WH .

JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (07) :641-650

[9] DECREASE IN LDL AND INCREASE IN HDL CONCENTRATIONS IN TYPE-II HYPERLIPOPROTEINEMIC PATIENTS ON LOW-DOSE COMBINATION THERAPY OF CHOLESTYRAMINE AND COMPLAMIN [J].

FEARS, R ;

FERRES, H ;

HAACKE, H ;

MADER, C ;

PARWARESCH, MR .

ATHEROSCLEROSIS, 1988, 69 (2-3) :97-101

[10]

GIANTURCO SH, 1991, CURR OPIN LIPIDOL, V2, P324

← 1 2 3 4 →